Genitourinary Cancers

David M. Nanus, MD, discusses the promise of immunotherapy and the continued role of surgery in the treatment in renal cell carcinoma.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses recent FDA approvals in renal cell carcinoma.

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.

The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).

The European Commission has approved cabozantinib (Cabometyx) for previously untreated patients with intermediate- or poor-risk advanced renal cell carcinoma.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the current treatment of patients with renal cell carcinoma.

Robert J. Motzer, MD, has been at the forefront of research into renal cell carcinoma for nearly 30 years, with his work contributing to the approval of at least 8 new drugs.

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.

Lauren C. Harshman, MD, discusses ongoing clinical trials examining the incorporation of immune therapies into practice.

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.

Raoul S. Concepcion, MD, FACS, discusses the current state of physicians the urology practice.

Since 2005, physician partners at Comprehensive Urologic Care have been using a form of clampless surgery, which they developed at their practice, for partial nephrectomies.

The European Commission has approved 2 new dosing schedules for nivolumab across several tumor types.

Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.

Combining ramucirumab with docetaxel in patients with locally advanced or unresectable metastatic urothelial carcinoma who progressed on platinum-based chemotherapy led to a positive trend, but not a statistically significant improvement, in overall survival.

An interim analysis revealed that the immunotherapy rocapuldencel-T is unlikely to meet any of the primary endpoints of the phase III ADAPT trial in patients with metastatic renal cell carcinoma.